CRNX Form 144 Filed for 16,000 Share Sale via Morgan Stanley ($574,240)

Rhea-AI Filing Summary

Crinetics Pharmaceuticals (CRNX) filed a Form 144 notifying a proposed sale of 16,000 common shares through Morgan Stanley Smith Barney LLC on 09/26/2025 with an aggregate market value of $574,240.00. The filing shows the shares were acquired as 10,000 via exercise of stock options on 09/26/2025 (paid in cash) and 6,000 as restricted stock units on 06/07/2024. The company reports 94,175,994 shares outstanding and discloses no securities sold by the reporting person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information.

Positive

• Full compliance with Rule 144 disclosure requirements, including broker, share counts, aggregate value, and acquisition/payment details
• No securities sold in the past three months by the reporting person, indicating this is not part of recent repeated disposals
• Filer's certification that they are not aware of undisclosed material adverse information

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for an insider sale; modest size and standard disclosure.

The Form 144 documents a proposed sale of 16,000 common shares valued at $574,240 to be executed through Morgan Stanley Smith Barney LLC on 09/26/2025. Acquisition details show 10,000 shares from option exercise paid in cash the same day and 6,000 shares from RSU vesting in 2024. No prior sales by the reporting person in the past three months are reported, indicating this is a standalone filing rather than part of a rapid disposal pattern. From an investor-analytics standpoint, the filing is a compliance disclosure without material indicators of company performance impact.

Corporate Governance Expert

TL;DR: Disclosure aligns with insider trading rules and includes the required certification; governance process appears followed.

The notice includes required elements: broker identity, number of shares, aggregate value, outstanding shares, acquisition dates, and payment method. The reporting individual affirms no undisclosed material adverse information and there are no reported sales in the prior three months. The timing—exercise and near-term sale recorded the same date for 10,000 shares—suggests the filer used Rule 144 mechanics to liquidate exercised shares, a common governance-compliant action when selling newly acquired shares. The filing demonstrates adherence to Form 144 requirements without revealing governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	16000	574240.00	94175994	09/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/26/2025	Exercise of Stock Options	Issuer			10000	09/26/2025	Cash
Common	06/07/2024	Restricted Stock Units	Issuer			6000	06/07/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Crinetics (CRNX) shares are proposed for sale in this Form 144?

The filing notifies a proposed sale of 16,000 common shares.

What is the aggregate market value of the shares to be sold for CRNX?

The aggregate market value reported is $574,240.00.

When is the proposed sale date listed on the CRNX Form 144?

The approximate date of sale is 09/26/2025.

Who is the broker handling the proposed sale of CRNX shares?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

How were the 16,000 CRNX shares acquired according to the filing?

The filing shows 10,000 shares were acquired by exercise of stock options on 09/26/2025 (paid in cash) and 6,000 shares were acquired as restricted stock units on 06/07/2024.

Has the reporting person sold any CRNX securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.